Lisa W Lekanne Dit Deprez1,2, Grégoire B Morand3,4,5, Christian Thüring1,6,7, Shila Pazahr6,7,8, Martin W Hüllner6,7,8, Martina A Broglie1,6,7. 1. Department of Otorhinolaryngology-Head and Neck Surgery, University Hospital Zurich, Frauenklinikstrasse 24, 8091, Zurich, Switzerland. 2. University of Groningen, Groningen, The Netherlands. 3. Department of Otorhinolaryngology-Head and Neck Surgery, University Hospital Zurich, Frauenklinikstrasse 24, 8091, Zurich, Switzerland. Gregoire.morand@mail.mcgill.ca. 4. University of Zurich, Zurich, Switzerland. Gregoire.morand@mail.mcgill.ca. 5. Department of Neuroradiology, University Hospital Zurich, Zurich, Switzerland. Gregoire.morand@mail.mcgill.ca. 6. University of Zurich, Zurich, Switzerland. 7. Department of Neuroradiology, University Hospital Zurich, Zurich, Switzerland. 8. Department of Nuclear Medicine, University Hospital Zurich, Zurich, Switzerland.
Abstract
PURPOSE: To investigate the predictive value of pretherapeutic metabolic tumor imaging using 18-fluorodeoxyglucose positron emission tomography (FDG-PET) for regional response in oropharyngeal cancer patients undergoing primary (chemo)radiation. METHODS: Retrospective analysis of oropharyngeal cancer patients treated with primary (chemo)radiation at the University Hospital Zurich from 2010 to 2019 with available FDG-PET. The SUVmax of the largest lymph node metastases was recorded. Regional response was assessed using posttherapeutic FDG-PET at 12 weeks and regional recurrence-free survival. RESULTS: 95 patients with a mean age of 68.5 years (SD 10.3) were included. The median pretherapeutic nodal SUVmax was 8.3 (interquartile range 4.4-13.3). A pretherapeutic nodal SUVmax above 6 significantly predicted poorer regional recurrence-free survival (log-rank test, P = 0.009) in univariate analysis. However, in multivariate analysis SUVmax above 6 was not significant in predicting regional recurrence-free survival (Cox regression P = 0.189). Clinical N category showed a trend in which a more severe stage had a poorer regional survival (Cox regression P = 0.073). CONCLUSION: The SUVmax of the largest lymph node metastasis seems to play a role in predicting regional response in oropharyngeal cancer patients, after stratifying for N category. More research is needed to investigate whether highly metabolically active disease is less likely to respond to chemoradiation.
PURPOSE: To investigate the predictive value of pretherapeutic metabolic tumor imaging using 18-fluorodeoxyglucose positron emission tomography (FDG-PET) for regional response in oropharyngeal cancer patients undergoing primary (chemo)radiation. METHODS: Retrospective analysis of oropharyngeal cancer patients treated with primary (chemo)radiation at the University Hospital Zurich from 2010 to 2019 with available FDG-PET. The SUVmax of the largest lymph node metastases was recorded. Regional response was assessed using posttherapeutic FDG-PET at 12 weeks and regional recurrence-free survival. RESULTS: 95 patients with a mean age of 68.5 years (SD 10.3) were included. The median pretherapeutic nodal SUVmax was 8.3 (interquartile range 4.4-13.3). A pretherapeutic nodal SUVmax above 6 significantly predicted poorer regional recurrence-free survival (log-rank test, P = 0.009) in univariate analysis. However, in multivariate analysis SUVmax above 6 was not significant in predicting regional recurrence-free survival (Cox regression P = 0.189). Clinical N category showed a trend in which a more severe stage had a poorer regional survival (Cox regression P = 0.073). CONCLUSION: The SUVmax of the largest lymph node metastasis seems to play a role in predicting regional response in oropharyngeal cancer patients, after stratifying for N category. More research is needed to investigate whether highly metabolically active disease is less likely to respond to chemoradiation.
Authors: Pascal Rüegg; Grégoire B Morand; Ken Kudura; Niels J Rupp; Martin W Hüllner; Martina A Broglie Journal: Head Neck Date: 2019-12-19 Impact factor: 3.147
Authors: Martina A Broglie; Wolfram Jochum; Angelika Michel; Tim Waterboer; Diana Foerbs; René Schoenegg; Sandro J Stoeckli; Michael Pawlita; Dana Holzinger Journal: Oral Oncol Date: 2017-05-25 Impact factor: 5.337
Authors: Martina A Broglie; Sandro J Stoeckli; Rafael Sauter; Philippe Pasche; Antoine Reinhard; Laurence de Leval; Gerhard F Huber; Thomas F Pezier; Alex Soltermann; Roland Giger; Andreas Arnold; Matthias Dettmer; Andre Arnoux; Martin Müller; Stefan Spreitzer; Florian Lang; Mathieu Lutchmaya; Edouard Stauffer; Vittoria Espeli; Francesco Martucci; Massimo Bongiovanni; Diana Foerbs; Wolfram Jochum Journal: Head Neck Date: 2017-07-10 Impact factor: 3.147
Authors: Maura L Gillison; Andy M Trotti; Jonathan Harris; Avraham Eisbruch; Paul M Harari; David J Adelstein; Richard C K Jordan; Weiqiang Zhao; Erich M Sturgis; Barbara Burtness; John A Ridge; Jolie Ringash; James Galvin; Min Yao; Shlomo A Koyfman; Dukagjin M Blakaj; Mohammed A Razaq; A Dimitrios Colevas; Jonathan J Beitler; Christopher U Jones; Neal E Dunlap; Samantha A Seaward; Sharon Spencer; Thomas J Galloway; Jack Phan; James J Dignam; Quynh Thu Le Journal: Lancet Date: 2018-11-15 Impact factor: 79.321
Authors: Anil K Chaturvedi; Eric A Engels; Ruth M Pfeiffer; Brenda Y Hernandez; Weihong Xiao; Esther Kim; Bo Jiang; Marc T Goodman; Maria Sibug-Saber; Wendy Cozen; Lihua Liu; Charles F Lynch; Nicolas Wentzensen; Richard C Jordan; Sean Altekruse; William F Anderson; Philip S Rosenberg; Maura L Gillison Journal: J Clin Oncol Date: 2011-10-03 Impact factor: 44.544
Authors: Panayiotis A Kyzas; Evangelos Evangelou; Despina Denaxa-Kyza; John P A Ioannidis Journal: J Natl Cancer Inst Date: 2008-05-13 Impact factor: 13.506
Authors: Alfred J Fleming; Stephen P Smith; Christopher M Paul; Nathan C Hall; Brett T Daly; Amit Agrawal; David E Schuller Journal: Laryngoscope Date: 2007-07 Impact factor: 3.325
Authors: L Tupchong; C B Scott; P H Blitzer; V A Marcial; L D Lowry; J R Jacobs; J Stetz; L W Davis; J B Snow; R Chandler Journal: Int J Radiat Oncol Biol Phys Date: 1991-01 Impact factor: 7.038
Authors: Rebecca S M Lim; Shakher Ramdave; Paul Beech; Baki Billah; Md Nazmul Karim; Julian A Smith; Adnan Safdar; Elizabeth Sigston Journal: Cancer Imaging Date: 2016-11-08 Impact factor: 3.909